CJC-1295 (No DAC) + Ipamorelin is a two-component lyophilised research blend combining materials associated with distinct upstream signalling pathways. It is supplied for controlled laboratory investigation of GHRH-receptor, ghrelin-receptor, pituitary-signalling and peptide-combination models.
Research material only
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
Product typeTwo-component peptide blend
Listed vial content10mg total blend
Component 1CJC-1295 (No DAC)
Component 2Ipamorelin
Research pathwaysGHRH and ghrelin-receptor signalling
FormLyophilised blend
Research context
The “CJC-1295 (No DAC)” designation is commonly used in the research-material market for a short-acting GHRH-pathway peptide, while published CJC-1295 studies frequently concern the albumin-binding DAC analogue. These materials must not be treated as interchangeable; identity should always be confirmed against the relevant product and batch documentation.
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue studied as an agonist at the ghrelin/growth-hormone-secretagogue receptor. The two components are therefore used in laboratory models examining separate but related upstream signalling mechanisms. Evidence concerning either component alone does not establish the identity, composition, performance or suitability of this blended material.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the product, listed vial content and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied as one lyophilised blend containing 10mg total listed vial content.
- The page does not state a component-by-component allocation; confirm any required ratio against the product or batch specification.
- Keep the vial sealed and protected from moisture, heat and direct light.
- Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.
Frequently asked questions
What is CJC-1295 (No DAC) + Ipamorelin?
It is a two-component lyophilised research blend containing materials designated CJC-1295 (No DAC) and Ipamorelin.
What does “No DAC” mean?
It indicates that the CJC-designated component is not the albumin-binding Drug Affinity Complex form described in long-acting CJC-1295 literature. Commercial naming is not fully standardised, so the exact identity should be checked against batch documentation.
Does 10mg mean 5mg of each component?
No component split is stated on this page. The 10mg label describes the total listed vial content; do not assume a 5mg/5mg allocation unless the product or batch specification explicitly confirms it.
How do the two components differ?
The CJC-1295 (No DAC) designation is associated with GHRH-receptor research, while Ipamorelin is studied at the ghrelin/growth-hormone-secretagogue receptor. They are distinct materials and should be evaluated independently as well as within any blend model.
Which vial sizes are available?
Current selectable vial sizes and availability are shown above. These controls update automatically as variations change.
Are laboratory results available?
A shield appears beside a variation only when a published result is available. No indicator means that no product-specific result is currently displayed for that variation.
How should the material be stored?
See the Storage Guidelines tab for the current handling guidance for sealed lyophilised material and reconstituted solution.
Information reviewed 29 August 2026.
Batch-specific analytical documentation
Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.
- Result available: a published report is available for the marked variation.
- Test pending: a sample has been submitted, but no completed result is being claimed.
- No indicator: no product-specific result is currently displayed for that variation.
Check the identifiers
Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.
Browse published lab results →
Storage and stability
Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.
| Form |
Suggested storage |
Important note |
| Sealed lyophilised material |
Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. |
Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling. |
| Reconstituted solution |
Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. |
Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed. |
No universal shelf-life is claimed
Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.
Published research
The sources below concern CJC-1295/GHRH-pathway analogues and Ipamorelin as individual research materials. Commercial “CJC-1295 (No DAC)” nomenclature is not fully standardised, and published CJC-1295 papers commonly describe the albumin-binding DAC analogue rather than the no-DAC material. The cited literature must therefore not be treated as confirmation of this blend’s identity or composition.
- PubChem. Ipamorelin — Compound Summary, CID 9831659. Reference structure, formula, sequence notation and computed molecular mass for Ipamorelin. View on PubChem ↗
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. Pharmacological profiling of Ipamorelin in pituitary-cell and animal models. View on PubMed ↗
- Davenport AP et al. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacological Reviews, 2005. Review of GHS-R1a nomenclature and growth-hormone-secretagogue receptor biology. View on PubMed ↗
- Jette L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. Preclinical characterisation of the albumin-binding CJC-1295 DAC analogue; this is not evidence for a no-DAC material. View on PubMed ↗
- Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006. Controlled human research with the long-acting DAC analogue, not the no-DAC designation on this product. View on PubMed ↗
Individual-component literature is not evidence for this blend
The cited studies do not establish the ratio, identity, purity, performance or suitability of the blended material supplied on this page. In particular, long-acting CJC-1295 DAC literature must not be attributed to a no-DAC material. Confirm both component identities, their allocation and the batch identifier against applicable product and analytical documentation.
